Las Vegas, NV – 
(NewMediaWire) – February 25, 2022 – BioAdaptives, Inc. (OTCMkts: BDPT), In reference to the previous Press Release of February 24, 2022, the Company announced today that it will continue providing Pluripain® and monitoring the use of this product by those suffering from the symptoms of Gadolinium Deposition Disease (GDD).
Edward E. Jacobs, M.D., CEO of the Company, stated, “We announced earlier the positive results of the GDD/PluriPain® survey conducted by Stanford University Professor Lorrin Koran, M.D.
“The pioneering work done by Dr. Koran is more properly characterized as a ‘survey,’ rather than a ‘study,’ as previously referenced, because of the use of different research protocols, including, for example, the need for IRB approval, physician supervision and standardized rating scales. The initial survey, which commenced in July 2021, covered a limited number of participants who complied with self-reporting requirements: 9 out of 15 of these participants surveyed reported positive outcomes to Dr. Koran. The 60% positive outcome reported is encouraging and warrants further study, but the use of statistics in such limited surveys should not be considered predictive of results that could be seen from larger numbers of patients.
“Following discussions with our medical consultants, we will continue surveying those suffering from symptoms related to GDD, as well as other, more common, painful conditions, by providing samples of PluriPain® while monitoring the reported effects. The Ayurvedic and TCM ingredients used in our formulas have been used for many centuries and we are confident that this product can be safely used to help manage these symptoms.
“In addition, the voluntary testimonial, previously provided by Regina Sutton, M.D., is a report of her personal, informed experience indicating that PluriPain® has had significant positive effects in managing her symptoms and should not be construed as a recommendation for a treatment for GDD.”
About BioAdaptives, Inc.
BioAdaptives, Inc. manufactures and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, anti-viral activity and immune system defense; resistance to stress; endurance; recovery from injury, illness and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best world-wide sources and utilize proprietary methods of enhancing the bioavailability of nutrients. The products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. Our current product line includes PrimiLungs™, PrimiCell® and PluriPain® for humans and Canine Regen®, Equine Regen® and Equine All-in-One™ for dogs and horses. Additional human products, to be introduced soon, are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; and improve overall emotional and physical wellness. The Company has also acquired patent rights to an oxygenated water process and will develop specialized water products through its MORO2, Inc. subsidiary.
BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.”
Additional information can be found at www.shopbioadaptives.com or in our SEC filings at https://www.sec.gov/cgi-bin/browse-edgar?company=bioadaptives&owner=exclude&action=getcompany
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.
Contact:
Investor Relations
BioAdaptives, Inc.
(702) 659-8829